Pancreatic cancer is one of the most aggressive types of
malignancies, responsible for the deaths of nearly 42,000 Americans in 2016, and for the first time surpassing breast cancer as the
third-leading cause of cancer related death in the United States.
Many patients diagnosed with pancreatic cancer can succumb to the
disease in less than a year, and the majority of these patients suffer
from severe pain associated with their disease.
One of the reasons for this disease's dismal prognosis is due to the
high rate at which the tumor recurs despite surgical removal.
Pancreatic Cancer
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.
Advertisement
‘Blocking nerve growth factor (NGF) signaling through inhibitors of NGF and its TRKA receptor reduces the potential of pancreatic cancer cells to migrate towards the surrounding nerves.’
Tweet it Now
The Translational Genomics Research Institute (TGen) has discovered potential drug targets to reduce pain in pancreatic cancer patients. TGen researchers have found that nerve growth factor (NGF), a neurotrophic factor, and its receptor TRKA are associated with perineural invasion (PNI), which is the ability of pancreatic cancer cells to invade surrounding nerves.
Blocking the NGF signaling through inhibitors of NGF and TRKA
reduces the potential of pancreatic cancer cells to migrate towards the
surrounding nerves, according to a TGen study published in the
scientific journal PLOS ONE.
![Microfluidic Device Captures Potential Biomarker for Early Pancreatic Cancer]( "Microfluidic Device Captures Potential Biomarker for Early Pancreatic Cancer")
Cancer cells are on the move in the bloodstream in the very early stage of pancreatic cancer. And it can be detected before cancer is diagnosed, claims research by the University of Michigan Health System.
"We have demonstrated that NGF signaling via the protein TRKA, between pancreatic cancer cells and surrounding nerves, is one of the molecular mechanisms involved in PNI," said Dr. Haiyong Han, Associate Professor of TGen's Clinical Translational Research Division and the senior author of the study.
"A potential reason for the high rate of relapse has been postulated to be the ability of the pancreatic cancer cells to invade the surrounding nerves," the study said.
This invasion is a highly coordinated process, involving signaling molecules secreted by both the nerves and the pancreatic cancer cells. The nerve ends are damaged and exposed by the pancreatic cancer cell invasion, resulting in pain.
The study found that this process also is associated with the growth and survival of pancreatic cancer cells. And, knocking down NGF or its receptors, TRKA and p75NTR, or treating TRKA with an inhibitor called GW441756, reduces the proliferation and migration of pancreatic cancer cells into the surrounding nerves.
The study concludes that additional research is needed, and that a clinical trial should be designed, using TRKA antagonists, to decrease the onset or worsening of pain for patients with advanced pancreatic cancer.
"We are trying to convince groups that have the TRKA inhibitor to allow us to test them in our systems and in the clinic as soon as possible," said Dr. Daniel Von Hoff, TGen's Distinguished Professor, Physician-In-Chief and a co-author of the study, who is one of the world's leading authorities on this disease.
The study - Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells - was published by PLOS ONE.
Source: Eurekalert
Microfluidic Device Captures Potential Biomarker for Early Pancreatic Cancer
Cancer cells are on the move in the bloodstream in the very early stage of pancreatic cancer. And it can be detected before cancer is diagnosed, claims research by the University of Michigan Health System.
Advertisement
"We have demonstrated that NGF signaling via the protein TRKA, between pancreatic cancer cells and surrounding nerves, is one of the molecular mechanisms involved in PNI," said Dr. Haiyong Han, Associate Professor of TGen's Clinical Translational Research Division and the senior author of the study.
"A potential reason for the high rate of relapse has been postulated to be the ability of the pancreatic cancer cells to invade the surrounding nerves," the study said.
This invasion is a highly coordinated process, involving signaling molecules secreted by both the nerves and the pancreatic cancer cells. The nerve ends are damaged and exposed by the pancreatic cancer cell invasion, resulting in pain.
The study found that this process also is associated with the growth and survival of pancreatic cancer cells. And, knocking down NGF or its receptors, TRKA and p75NTR, or treating TRKA with an inhibitor called GW441756, reduces the proliferation and migration of pancreatic cancer cells into the surrounding nerves.
The study concludes that additional research is needed, and that a clinical trial should be designed, using TRKA antagonists, to decrease the onset or worsening of pain for patients with advanced pancreatic cancer.
"We are trying to convince groups that have the TRKA inhibitor to allow us to test them in our systems and in the clinic as soon as possible," said Dr. Daniel Von Hoff, TGen's Distinguished Professor, Physician-In-Chief and a co-author of the study, who is one of the world's leading authorities on this disease.
The study - Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells - was published by PLOS ONE.
Source: Eurekalert
New Device may Help in Early Diagnosis of Pancreatic Cancer
Early diagnosis of pancreatic cancer could be cheaper and faster thanks to a new device being developed by researchers.
Advertisement
 Enzyme Linked to Aggressive Pancreatic Cancer Offers Potential Clinical AdvancesAn enzyme is being discovered by Mayo Clinic researchers which they say is tightly linked to how aggressive pancreatic cancer will be in a patient. | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.
Combination treatment with TALZENNA and XTANDI was found to benefit prostate cancer patients, revealed study.
In leukemia patients, reduced amounts of dietary vitamin A is associated with a higher risk and severity of pancreatitis.